Psychedelic Research in
Costa Rica
Costa Rica has a tightly controlled legal framework for classic psychedelics and related psychoactives, with research and medical use governed through general drug-control and biomedical-research rules rather than any psychedelic-specific pathway. The country's ecosystem appears small: Blossom currently links no active trials and no events, while the available public evidence points more to isolated clinical and academic capacity than to a dedicated psychedelic research hub.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Costa Rica.
- 1
The public regulatory frame is clear and conservative: Costa Rica relies on general narcotics and psychotropics law rather than a bespoke psychedelic policy.
- 2
The research environment appears limited rather than absent, with biomedical governance infrastructure in place but no Blossom-linked active psychedelic trials.
- 3
University of Costa Rica has broad health-science and laboratory capacity, which could support future clinical or translational work, but the sources reviewed do not show a dedicated psychedelic programme.
- 4
Any ketamine or similar medical-clinic activity should be interpreted as conventional controlled-medicine practice, not evidence of legal access to classic psychedelics.
- 5
For Blossom's purposes, Costa Rica looks more like a strict-access jurisdiction with occasional private or ceremonial grey zones than a formal emerging psychedelic market.
Research Snapshot
Blossom currently tracks no country-linked psychedelic clinical trials for Costa Rica, but the page does include 7 stakeholders.
Missing linked records are database coverage signals, not proof that no local policy discussion, care or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 7
- Events
- 0
None marked active
No linked trials
Linked organisations
No linked events
Top Compounds
No headline compound signal is available from linked country trials yet.
Top Study Topics
No study-topic signal is available from linked country trials yet.
Medical Access Snapshot
Costa Rica follows a strict national drug-scheduling framework derived from international conventions (the Ley No 8204 drug law) that criminalizes production, trafficking and non-authorized uses of most classic psychedelics, while permitting conventional medical use of anesthetics and controlled medicines. In practice, ketamine is available and used in medical and private-clinic settings (including international medical-tourism offerings); other compounds (psilocybin, MDMA, DMT, mescaline, 2C-X, 5-MeO-DMT) are treated as controlled/illegal except where...
Regulatory Status
Costa Rica's Ministry of Health publishes Ley No. 8204 and related drug-control regulations as the core framework for psychotropics and narcotics, and the country also regulates biomedical research through CONIS and the biomedical-research law. That supports a restrictive baseline: classic psychedelics are generally controlled/illegal outside authorised research or other explicit legal exceptions, while standard medical use of controlled medicines remains possible. I could not verify a psychedelic-specific legal access pathway or any formal public authorisation for broad non-research psychedelic use, so private-clinic or retreat claims should be treated as uncertain unless independently documented.
Country Details
- Region
- North America
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Costa Rica follows a strict national drug-scheduling framework derived from international conventions (the Ley No 8204 drug law) that criminalizes production, trafficking and non-authorized uses of most classic psychedelics, while permitting conventional medical use of anesthetics and controlled...
Open access guide →Psychedelic Stakeholders in Costa Rica
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Costa Rica.